Incretin Atlas › Molecules › Efpeglenatide
Efpeglenatide
GLP-1 · s.c. · Hanmi
Summary
- Also known as
- Hanmi / Sanofi
- Mechanism
- GLP-1
- Route
- s.c.
- Company
- Hanmi
- Highest development stage
- —
- Status (as of data cut)
- Positive CVOT (AMPLITUDE-O); development paused verify
- Next milestone
- —
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Outcome trials
Cardiovascular and kidney outcome trials
AMPLITUDE-O efpeglenatide 4/6 mg vs placebo · T2D + CVD/CKD · n = 4076 · 2021 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary Primary MACE: first nonfatal MI, nonfatal stroke, or death from cardiovascular or undetermined causes | 0.73 | 0.58–0.92 | 189 vs 125 | verified |
| Cardiovascular death Cardiovascular mortality | 0.72 | 0.50–1.03 | 75 vs 50 | verified |
| All-cause death Total mortality (death from any cause) | 0.78 | 0.58–1.06 | 111 vs 69 | verified |
| Myocardial infarction Myocardial infarction (fatal or non-fatal) | 0.75 | 0.54–1.05 | 91 vs 58 | verified |
| Stroke Stroke (fatal or non-fatal) | 0.74 | 0.47–1.17 | 47 vs 31 | verified |
| Hospitalisation for heart failure Hospitalization for heart failure (adjudicated; listed as 'Heart failure' in Table 2) | 0.61 | 0.38–0.98 | 40 vs 31 | verified |
| Kidney composite Composite renal outcome (key secondary): incident macroalbuminuria (UACR >300 plus an increase of at least 30% from baseline), sustained eGFR decrease of at lea | 0.68 | 0.57–0.79 | 353 vs 250 | verified |
| Expanded MACE (MACE + revasc. + UA) Expanded MACE: MACE (nonfatal MI, nonfatal stroke, death from CV or undetermined causes) plus coronary revascularization or hospitalization for unstable angina | 0.79 | 0.65–0.96 | 257 vs 158 | verified |
| New macroalbuminuria Incident macroalbuminuria: UACR >300 mg/g (>33.9 mg/mmol) plus an increase in UACR of at least 30% from baseline | 0.68 | 0.58–0.80 | 348 vs 244 | verified |
| Coronary revascularisation Coronary revascularization | 0.93 | 0.69–1.26 | 126 vs 66 | verified |
| Hospitalisation for unstable angina Unstable angina (hospitalization for unstable angina, component of expanded MACE) | 0.55 | 0.13–2.35 | 6 vs 4 | verified |
Verbatim quotes (11)
- 3-point MACE · Results, Trial Outcomes; Table 2
189 of 2717 participants (7.0%) assigned to receive efpeglenatide and 125 of 1359 participants (9.2%) assigned to receive placebo had at least one MACE (...hazard ratio, 0.73; 95% CI, 0.58 to 0.92
- Cardiovascular death · Table 2
Cardiovascular mortality 75 (2.8) 1.5 50 (3.7) 2.1 0.72 (0.50–1.03)
- All-cause death · Table 2
Total mortality 111 (4.1) 2.2 69 (5.1) 2.8 0.78 (0.58–1.06)
- Myocardial infarction · Table 2
Myocardial infarction 91 (3.3) 1.9 58 (4.3) 2.4 0.75 (0.54–1.05)
- Stroke · Table 2
Stroke 47 (1.7) 1.0 31 (2.3) 1.3 0.74 (0.47–1.17)
- Hospitalisation for heart failure · Table 2
Heart failure 40 (1.5) 0.8 31 (2.3) 1.3 0.61 (0.38–0.98)
- Kidney composite · Abstract; Table 2
A composite renal outcome event ... occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79
- Expanded MACE (MACE + revasc. + UA) · Table 2. Adjudicated First Events (footnote §)
Expanded MACE composite outcome event§ 257 (9.5) 5.4 158 (11.6) 6.8 0.79 (0.65–0.96) 0.02
- New macroalbuminuria · Table 2. Adjudicated First Events (footnote ¶)
Incident macroalbuminuria 348 (12.8) 7.6 244 (18.0) 11.3 0.68 (0.58–0.80)
- Coronary revascularisation · Table 2. Adjudicated First Events
Coronary revascularization 126 (4.6) 2.6 66 (4.9) 2.8 0.93 (0.69–1.26)
- Hospitalisation for unstable angina · Table 2. Adjudicated First Events
Unstable angina 6 (0.2) 0.1 4 (0.3) 0.2 0.55 (0.13–2.35)
Registered trials (1)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| AMPLITUDE-O Effect of Efpeglenatide on Cardiovascular Outcomes | CV outcomes | Phase 3 | terminated | 2018-04 → 2020-12 | 4076 | MACE HR 0.73 (0.58–0.92) | NCT03496298 |
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Efpeglenatide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/efpeglenatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.